- Home
- AVPT vs FOLD Comparison
AVPT vs FOLD Comparison
Compare AVPT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- FOLD
- Stock Information
- Founded
- AVPT 2001
- FOLD 2002
- Country
- AVPT United States
- FOLD United States
- Employees
- AVPT N/A
- FOLD N/A
- Industry
- AVPT Computer Software: Prepackaged Software
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- AVPT Technology
- FOLD Health Care
- Exchange
- AVPT Nasdaq
- FOLD Nasdaq
- Market Cap
- AVPT 3.0B
- FOLD 2.9B
- IPO Year
- AVPT N/A
- FOLD 2007
- Fundamental
- Price
- AVPT $18.85
- FOLD $5.98
- Analyst Decision
- AVPT Buy
- FOLD Buy
- Analyst Count
- AVPT 5
- FOLD 10
- Target Price
- AVPT $17.00
- FOLD $16.22
- AVG Volume (30 Days)
- AVPT 877.0K
- FOLD 4.9M
- Earning Date
- AVPT 05-08-2025
- FOLD 05-01-2025
- Dividend Yield
- AVPT N/A
- FOLD N/A
- EPS Growth
- AVPT N/A
- FOLD N/A
- EPS
- AVPT N/A
- FOLD N/A
- Revenue
- AVPT $349,012,000.00
- FOLD $543,141,000.00
- Revenue This Year
- AVPT $18.61
- FOLD $21.87
- Revenue Next Year
- AVPT $18.52
- FOLD $22.19
- P/E Ratio
- AVPT N/A
- FOLD N/A
- Revenue Growth
- AVPT 21.70
- FOLD 28.25
- 52 Week Low
- AVPT $8.06
- FOLD $6.20
- 52 Week High
- AVPT $19.90
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- AVPT 77.79
- FOLD 28.44
- Support Level
- AVPT $16.56
- FOLD $5.82
- Resistance Level
- AVPT $17.30
- FOLD $7.71
- Average True Range (ATR)
- AVPT 0.49
- FOLD 0.31
- MACD
- AVPT 0.29
- FOLD -0.06
- Stochastic Oscillator
- AVPT 84.40
- FOLD 8.47
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.